Management team

Eva Arlander

Born in 1964. Pharmacist, Ph.D. in Medical Science. Executive Vice President Commercial. Project Manager of Xerclear. Medivir employee since 2004. Previous positions include Project Manager and Manager of AstraZeneca’s clinical research operation.
Medivir shareholding: 0.
Stock options* 2007–2012: 10,000.

Option program* 2010-2013: 9,500 warrants, 9,500 stock options.

Charlotte Edenius

Born in 1958. MD and PhD (Karolinska Institutet, Stockholm). Executive Vice President R&D. Medivir employee since 2010. Previously Senior Vice President Preclinical and Clinical R & D, Orexo, Chief scientific Officer at Biolipox and various positions within Clinical R&D AstraZeneca, Södertälje.
Medivir shareholding (family): 3,100 class B.

Maris Hartmanis

Born in 1953. Ph.D. in Biochemistry and Associate Professor at the Royal Institute of Technology, Stockholm. President and CEO at Medivir and CEO of BioPhausia. Employed in 2011.
More than 25 years within the Life Science industry in senior positions at companies like BioPhausia, Gambro, Amersham and Pharmacia.
Medivir shareholding: 10,000 class B.

Christina Kassberg

Born in 1968. B.Sc. (Econ.) Executive Vice President Finance & HR. Medivir employee since 2000. Previously Controller of Medivir AB, Accounting Manager at Skandia Link Multifond and Auditor at Öhrlings PricewaterhouseCoopers.
Medivir shareholding (family): 13,367 class B.

Option program* 2010-2013: 9,500 warrants, 9,500 stock options.

Jens Kristensen

Born in 1958. Executive Vice President Clinical. MD from Denmark and PhD from the University of Uppsala. Medivir employee since 2011. Previously Chief Medical Officer and VP Clinical Development at Karo Bio AB and Melacure AB and before that various positions within Neuroscience R&D at AstraZeneca. In total 13 years within the medical industry and 15 years of clinical experience. Board certified specialist in Anaestesia, Intensive Care and Pharmaceutical Medicine.
Medivir shareholding: 1,000 class B.

Rein Piir

Born in 1958. B.Sc. (Econ.) Executive Vice President Corporate Affairs & IR. Medivir employee since 2000. Previously senior positions include Healthcare & Research at D. Carnegie AB and Research & Strategy at SPP.
Medivir shareholding: 0.

Option program* 2010-2013: 9,500 warrants, 9,500 stock options.

Paul Wallace

Born in 1962. Ph.D. University of Cambridge. Executive Vice President Business Development. Employed since 2000. Previously Business Development Manager at Peptide Therapeutics plc and Director of Research at Eclagen, both in the UK.
Medivir shareholding: 0.
Stock options* 2007-2012: 22,000.

Option program* 2010-2013: 9,500 warrants, 9,500 stock options.

Håkan Wallin

Born 1962. BA from Stockholm University and CEFA from Stockholm School of Economics. Executive Vice President Corporate Development. Employed since 2010. Previous appointments: Chairman of Aerodyn AB, member of the Board of Directors and CEO of Libertas Capital Nordic AB, partner and head of life-science at ABG Sundal Collier AB’s Corporate Finance department, Senior Manager at Ernst & Young’s Corporate Finance department, and auditor at Arthur Andersen AB.
Medivir shareholding: 2,600 class B.

Option program* 2010-2013: 9,500 warrants, 9,500 stock options.